Arrivobio Raises $45M In Series B Financing To Advance Pipeline
11/29/23, 1:03 PM
Location
morrisvilleMoney raised
$45 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
Arrivo, Rex Health Ventures, Solas Bio Ventures Emerging Healthcare Fund, L.P., Orlando Health Ventures
Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.
Company Info
Location
morrisville, new york, united states
Additional Info
SP-624 is a small molecule that selectively activates the SIRT6 enzyme, a novel epigenetic mechanism known to modulate gene expression, metabolism and DNA repair. Recent published literature suggests that human females and males exhibit gene expression changes in opposite directions when depressed.1 The results of Arrivo’s Phase 2 study with SP-624 appear to support this finding by demonstrating that female subjects on SP-624 experienced early and robust alleviation of depressive symptoms, unlike male patients in the study.